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SIR,  
We are grateful to Drs Tecer and Kucuk for their interest and comment on 
our recent publication on disease-modifying anti-rheumatic drugs (DMARDs) 
for osteoarthritis (OA).(1)  
We agree with the current view that identifying distinct phenotypes in OA, 
which have different responses to mechanistically diverse treatments, is an 
important aim in optimising the management of people with OA. In relation 
to DMARDs, the major endo-phenotypic variable of interest is the presence of 
joint inflammation.(2) The epitome of OA driven by inflammation is erosive 
hand OA. We therefore conducted a subgroup analysis of individuals with 
erosive hand OA and did not find a difference between DMARDs and placebo 
for this phenotype. Although limited by a small sample size (n=193), the 
findings were markedly homogenous (I2 = 0.0%, p value 0.846). This 
suggests that inflammation in OA is different from that in RA. 
Certainly, it is widely accepted that some individuals with OA report 
neuropathic-like pain. Its prevalence in people with knee OA varies by 
population, but generally affects a minority of individuals.(3) In our location 
in the East Midlands, United Kingdom, the prevalence of neuropathic-like 
pain in community-derived people with chronic knee pain is 14%.(4)  
Unfortunately, we were unable to examine people with neuropathic-like pain 
separately in our meta-analysis as this was not measured or reported for the 
trials. However, it is unlikely that the presence of this type of pain, estimated 
to affect 23% of study populations,(3) would explain the lack of efficacy of 
DMARDs for pain relief in OA. In fact, similar rates of neuropathic-like pain 
have been reported in rheumatoid arthritis (RA) and other inflammatory 
arthritides (5) for which DMARDs are commonly used. Therefore the reasons 
why DMARDs are effective for RA, but not OA, cannot be fully explained by 
the presence of neuropathic-like pain in OA.  
Nevertheless, better characterisation of pain phenotypes in OA patients is 
important and we suggest that clinical trials should assess important baseline 
characteristics that may serve as subgroup factors, such as the presence of 
neuropathic-like pain, synovitis, and pain elsewhere. Such information may 
not be of primary interest for individual trials, however, its assessment would 
provide an excellent opportunity for future individual patient data meta-
analyses to identify predictors of treatment response. 
In conclusion, further research on predictors of response to treatments is 
important and should be facilitated by the assessment of potential predictors 
in all clinical trials in OA, irrespective of whether these baseline measures are 
useful for the individual trials.  
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